^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
Soltamox (tamoxifen citrate)
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Jazz
Drug class:
Estrogen receptor modulator
Related drugs:
2ms
PRO30178: Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer (clinicaltrials.gov)
P2, N=37, Active, not recruiting, Medical College of Wisconsin | Trial completion date: Jul 2024 --> Mar 2025
Trial completion date
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
|
HER-2 positive • HER-2 negative • PGR positive
|
letrozole • anastrozole • exemestane • Soltamox (tamoxifen citrate)
4ms
Umbrella Trial Testing Integrative Subtype Targeted Therapeutics in Estrogen Receptor Positive, HER2-Negative Breast Cancer (clinicaltrials.gov)
P2, N=19, Active, not recruiting, Stanford University | Recruiting --> Active, not recruiting | N=150 --> 19
Enrollment closed • Enrollment change
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
Piqray (alpelisib) • fulvestrant • zotatifin (eFT226) • Soltamox (tamoxifen citrate)
5ms
Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer (clinicaltrials.gov)
P3, N=394, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jul 2024 --> May 2025
Trial completion date • Metastases
|
ER (Estrogen receptor) • PGR (Progesterone receptor)
|
Avastin (bevacizumab) • letrozole • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Soltamox (tamoxifen citrate)
5ms
MCN_Tam: Chemoprevention With Tamoxifen in Pre-Invasive Pancreas Mucinous Cystic Neoplasms Not Undergoing Immediate Resection (clinicaltrials.gov)
P1, N=15, Not yet recruiting, University of Nebraska | Initiation date: May 2024 --> Sep 2024
Trial initiation date
|
Soltamox (tamoxifen citrate)
6ms
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer (clinicaltrials.gov)
P3; Trial completion date: Mar 2024 --> Oct 2032
Trial completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative
|
Oncotype DX Breast Recurrence Score®Test
|
letrozole • anastrozole • exemestane • Soltamox (tamoxifen citrate)
6ms
The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer (clinicaltrials.gov)
P2, N=30, Completed, Johns Hopkins University | Active, not recruiting --> Completed
Trial completion
|
ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • PGR positive
|
letrozole • exemestane • Soltamox (tamoxifen citrate)
8ms
Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery (clinicaltrials.gov)
P2, N=74, Not yet recruiting, University of Chicago
New P2 trial
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive
|
docetaxel • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • letrozole • goserelin acetate • Soltamox (tamoxifen citrate)
8ms
MCN_Tam: Chemoprevention With Tamoxifen in Pre-Invasive Pancreas Mucinous Cystic Neoplasms Not Undergoing Immediate Resection (clinicaltrials.gov)
P1, N=15, Not yet recruiting, University of Nebraska
New P1 trial
|
Soltamox (tamoxifen citrate)
8ms
Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer (clinicaltrials.gov)
P2, N=81, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: May 2024 --> Feb 2025
Trial completion date • Metastases
|
ER (Estrogen receptor) • NCOA3 (Nuclear Receptor Coactivator 3)
|
ER positive • HER-2 negative • ER positive + HER-2 negative
|
Zonalta (Z-endoxifen hydrochloride) • Soltamox (tamoxifen citrate)
11ms
EMPRESS: Preoperative Window Opportunity Study With Giredestrant or Tamoxifen in Premenopausal Women With ER+/HER2[-] & Ki67≥10% (clinicaltrials.gov)
P2, N=92, Recruiting, MedSIR
Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
HER-2 negative
|
giredestrant (GDC-9545) • Soltamox (tamoxifen citrate)
1year
ASPIRE: Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis (clinicaltrials.gov)
P2, N=38, Completed, Emory University | Active, not recruiting --> Completed
Trial completion
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HER-2 negative • PGR positive
|
Ibrance (palbociclib) • fulvestrant • letrozole • anastrozole • exemestane • Soltamox (tamoxifen citrate)
1year
Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer (clinicaltrials.gov)
P2/3, N=260, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2023 --> Oct 2024
Trial completion date
|
BRAF (B-raf proto-oncogene)
|
Mekinist (trametinib) • paclitaxel • letrozole • pegylated liposomal doxorubicin • topotecan • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • Soltamox (tamoxifen citrate)
1year
ETHAN - ET for Male BC (clinicaltrials.gov)
P2, N=60, Recruiting, Jose Pablo Leone | Not yet recruiting --> Recruiting
Enrollment open
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HR positive • HER-2 negative • HR positive + HER-2 negative
|
Verzenio (abemaciclib) • anastrozole • Firmagon (degarelix) • Soltamox (tamoxifen citrate)
over1year
PRO30178: Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer (clinicaltrials.gov)
P2, N=37, Active, not recruiting, Medical College of Wisconsin | Trial completion date: Jul 2023 --> Jul 2024
Trial completion date
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
|
HER-2 positive • HER-2 negative • PGR positive
|
letrozole • anastrozole • exemestane • Soltamox (tamoxifen citrate)
over1year
Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer (clinicaltrials.gov)
P2, N=81, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: May 2023 --> May 2024
Trial completion date • Metastases
|
ER (Estrogen receptor)
|
ER positive • HER-2 negative • ER positive + HER-2 negative
|
Zonalta (Z-endoxifen hydrochloride) • Soltamox (tamoxifen citrate)
over1year
ETHAN - ET for Male BC (clinicaltrials.gov)
P2, N=60, Not yet recruiting, Jose Pablo Leone | Initiation date: Feb 2023 --> Oct 2023
Trial initiation date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HR positive • HER-2 negative • HR positive + HER-2 negative
|
Verzenio (abemaciclib) • anastrozole • Firmagon (degarelix) • Soltamox (tamoxifen citrate)
over1year
ASPIRE: Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis (clinicaltrials.gov)
P2, N=38, Active, not recruiting, Emory University | Trial completion date: Aug 2023 --> Dec 2023 | Trial primary completion date: Aug 2023 --> Dec 2023
Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HER-2 negative • PGR positive
|
Ibrance (palbociclib) • fulvestrant • letrozole • anastrozole • exemestane • Soltamox (tamoxifen citrate)
over1year
Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer (clinicaltrials.gov)
P2, N=81, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: May 2022 --> May 2023
Trial completion date • Metastases
|
ER (Estrogen receptor)
|
ER positive • HER-2 negative • ER positive + HER-2 negative
|
Zonalta (Z-endoxifen hydrochloride) • Soltamox (tamoxifen citrate)
over1year
Umbrella Trial Testing Integrative Subtype-Targeted Therapeutics in HR+ /HER2-Negative Breast Cancer (clinicaltrials.gov)
P2, N=150, Recruiting, Stanford University | Not yet recruiting --> Recruiting
Enrollment open
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HER-2 negative
|
Piqray (alpelisib) • fulvestrant • zotatifin (eFT226) • Soltamox (tamoxifen citrate)
over1year
Umbrella Trial Testing Integrative Subtype-Targeted Therapeutics in HR+ /HER2-Negative Breast Cancer (clinicaltrials.gov)
P2, N=150, Not yet recruiting, Stanford University | N=100 --> 150
Enrollment change
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HER-2 negative
|
Piqray (alpelisib) • fulvestrant • zotatifin (eFT226) • Soltamox (tamoxifen citrate)
over1year
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer (clinicaltrials.gov)
P3; N=10000 --> 5083 | Trial completion date: Feb 2023 --> Mar 2024
Trial completion date • Enrollment change
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative
|
Oncotype DX Breast Recurrence Score®Test
|
letrozole • anastrozole • exemestane • Soltamox (tamoxifen citrate)
almost2years
Umbrella Trial Testing Integrative Subtype-Targeted Therapeutics in HR+ /HER2-Negative Breast Cancer (clinicaltrials.gov)
P2, N=100, Not yet recruiting, Stanford University | N=264 --> 100
Enrollment change
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HER-2 negative
|
Piqray (alpelisib) • fulvestrant • zotatifin (eFT226) • Soltamox (tamoxifen citrate)
2years
The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer (clinicaltrials.gov)
P2 | N=30 | Active, not recruiting | Sponsor: Johns Hopkins University | Recruiting --> Active, not recruiting | Trial completion date: Nov 2022 --> Nov 2023
Trial completion date • Enrollment closed
|
ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • PGR positive • PGR expression
|
MammaPrint • BluePrint
|
letrozole • exemestane • Soltamox (tamoxifen citrate)
2years
Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer (clinicaltrials.gov)
P1b; Active, not recruiting --> Terminated; Drug manufacturer decision to terminate development.
Combination therapy • Trial termination
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HER-2 negative • PGR positive
|
FoundationOne® CDx
|
Truseltiq (infigratinib) • Soltamox (tamoxifen citrate)
2years
Study of Infigratinib in Combination With Tamoxifen or With Fulvestrant and Palbociclib in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer (clinicaltrials.gov)
P1b; Recruiting --> Active, not recruiting | N=12 --> 4
Combination therapy • Enrollment change • Enrollment closed
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HER-2 negative • PGR positive
|
FoundationOne® CDx
|
Ibrance (palbociclib) • fulvestrant • Truseltiq (infigratinib) • Soltamox (tamoxifen citrate)
2years
ASPIRE: Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis (clinicaltrials.gov)
P2, N=38, Active, not recruiting, Emory University | Recruiting --> Active, not recruiting | Trial completion date: Aug 2022 --> Aug 2023 | Trial primary completion date: Aug 2022 --> Aug 2023
Enrollment closed • Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HER-2 negative • PGR positive
|
Ibrance (palbociclib) • fulvestrant • letrozole • anastrozole • exemestane • Soltamox (tamoxifen citrate)
over2years
ETHAN - ET for Male BC (clinicaltrials.gov)
P2, N=60, Not yet recruiting, Jose Pablo Leone
New P2 trial
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HR positive • HER-2 negative • HR positive + HER-2 negative
|
Verzenio (abemaciclib) • anastrozole • Firmagon (degarelix) • Soltamox (tamoxifen citrate)
over2years
Umbrella Trial Testing Integrative Subtype-Targeted Therapeutics in HR+ /HER2-Negative Breast Cancer (clinicaltrials.gov)
P2, N=264, Not yet recruiting, Stanford University | Initiation date: Mar 2022 --> Jan 2023
Trial initiation date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HER-2 negative
|
Piqray (alpelisib) • Truseltiq (infigratinib) • letrozole • amcenestrant (SAR439859) • Soltamox (tamoxifen citrate)
almost3years
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer (clinicaltrials.gov)
P3; Trial completion date: Feb 2022 --> Feb 2023 | Trial primary completion date: Feb 2022 --> Feb 2023
Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative
|
Oncotype DX Breast Recurrence Score®Test
|
letrozole • anastrozole • exemestane • Soltamox (tamoxifen citrate)
almost3years
Umbrella Trial Testing Integrative Subtype-Targeted Therapeutics in HR+ /HER2-Negative Breast Cancer (clinicaltrials.gov)
P2, N=264, Not yet recruiting, Stanford University | Initiation date: Dec 2021 --> Mar 2022
Trial initiation date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HER-2 negative
|
Piqray (alpelisib) • Truseltiq (infigratinib) • letrozole • amcenestrant (SAR439859) • Soltamox (tamoxifen citrate)
almost3years
Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer (clinicaltrials.gov)
P2, N=70, Recruiting, Emily Marcinkowski
Clinical • New P2 trial
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
ER positive • HER-2 negative
|
letrozole • anastrozole • exemestane • Soltamox (tamoxifen citrate)
almost3years
The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer (clinicaltrials.gov)
P2; Trial completion date: Nov 2021 --> Nov 2022 | Trial primary completion date: Nov 2021 --> Nov 2022
Trial completion date • Trial primary completion date
|
ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • PGR positive • PGR expression
|
MammaPrint
|
letrozole • exemestane • Soltamox (tamoxifen citrate)
3years
Umbrella Trial Testing Integrative Subtype-Targeted Therapeutics in HR+ /HER2-Negative Breast Cancer (clinicaltrials.gov)
P2, N=264, Not yet recruiting, Stanford University
New P2 trial
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HER-2 negative
|
Piqray (alpelisib) • Truseltiq (infigratinib) • letrozole • amcenestrant (SAR439859) • Soltamox (tamoxifen citrate)
3years
ASPIRE: Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis (clinicaltrials.gov)
P2, N=42, Recruiting, Emory University | Trial completion date: Jun 2021 --> Aug 2022 | Trial primary completion date: Jun 2021 --> Aug 2022
Clinical • Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HER-2 negative • PGR positive
|
Ibrance (palbociclib) • fulvestrant • letrozole • anastrozole • exemestane • Soltamox (tamoxifen citrate)
3years
PRO30178: Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer (clinicaltrials.gov)
P2, N=37, Active, not recruiting, Medical College of Wisconsin | Trial completion date: Jul 2022 --> Jul 2023 | Trial primary completion date: Jul 2021 --> Jul 2022
Clinical • Trial completion date • Trial primary completion date
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
|
HER-2 positive • HER-2 negative • PGR positive
|
letrozole • anastrozole • exemestane • Soltamox (tamoxifen citrate)
over3years
Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer (clinicaltrials.gov)
P2, N=81, Active, not recruiting, National Cancer Institute (NCI) | Trial primary completion date: Jan 2022 --> Nov 2020
Clinical • Trial primary completion date
|
ER (Estrogen receptor)
|
ER positive • HER-2 negative • ER positive + HER-2 negative
|
Zonalta (Z-endoxifen hydrochloride) • Soltamox (tamoxifen citrate)
over3years
SOFT: Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer (clinicaltrials.gov)
P3, N=3066, Active, not recruiting, International Breast Cancer Study Group | Trial completion date: Dec 2031 --> Dec 2025
Clinical • Trial completion date
|
ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HR positive
|
exemestane • triptorelin • Soltamox (tamoxifen citrate)
almost4years
Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer (clinicaltrials.gov)
P2, N=80, Active, not recruiting, National Cancer Institute (NCI) | Trial primary completion date: Jan 2021 --> Jan 2022
Clinical • Trial primary completion date
|
ER (Estrogen receptor)
|
ER positive • HER-2 negative • ER positive + HER-2 negative
|
Zonalta (Z-endoxifen hydrochloride) • Soltamox (tamoxifen citrate)
almost4years
The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer (clinicaltrials.gov)
P2, N=30, Recruiting, Johns Hopkins University | Trial completion date: Nov 2020 --> Nov 2021 | Trial primary completion date: Nov 2020 --> Nov 2021
Trial completion date • Trial primary completion date
|
ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • PGR positive
|
letrozole • exemestane • Soltamox (tamoxifen citrate)
4years
Study of Infigratinib in Combination With Tamoxifen or With Fulvestrant and Palbociclib in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer (clinicaltrials.gov)
P1b;Not yet recruiting --> Recruiting
Combination therapy • Enrollment open
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HER-2 negative • PGR positive
|
FoundationOne® CDx
|
Ibrance (palbociclib) • fulvestrant • Truseltiq (infigratinib) • Soltamox (tamoxifen citrate)
4years
Combination therapy • Enrollment change
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HER-2 negative • PGR positive
|
FoundationOne® CDx
|
Ibrance (palbociclib) • fulvestrant • Truseltiq (infigratinib) • Soltamox (tamoxifen citrate)
over4years
N9831: Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer (clinicaltrials.gov)
P3, N=3436, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed
Clinical • Trial completion
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 positive • ER negative • PGR negative
|
paclitaxel • doxorubicin hydrochloride • Soltamox (tamoxifen citrate)
Share via
